Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in … – Business Wire (press release)
|
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR–T Trial of Axicabtagene Ciloleucel in …
Business Wire (press release) BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE) today announced two plenary presentations of positive data from the primary analysis of ZUMA-1 for its lead CAR–T candidate, axicabtagene ciloleucel, in patients with refractory aggressive B-cell … |
